Cellectis (CLLS) Competitors $1.87 -0.04 (-2.09%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CLLS vs. ESPR, RNAC, DSGN, AKBA, VALN, FDMT, AMLX, TNGX, CYRX, and NLTXShould you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Esperion Therapeutics (ESPR), Cartesian Therapeutics (RNAC), Design Therapeutics (DSGN), Akebia Therapeutics (AKBA), Valneva (VALN), 4D Molecular Therapeutics (FDMT), Amylyx Pharmaceuticals (AMLX), Tango Therapeutics (TNGX), Cryoport (CYRX), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry. Cellectis vs. Esperion Therapeutics Cartesian Therapeutics Design Therapeutics Akebia Therapeutics Valneva 4D Molecular Therapeutics Amylyx Pharmaceuticals Tango Therapeutics Cryoport Neoleukin Therapeutics Cellectis (NASDAQ:CLLS) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability, community ranking and valuation. Which has higher earnings & valuation, CLLS or ESPR? Cellectis has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectis$9.19M11.31-$101.06M-$1.30-1.44Esperion Therapeutics$116.33M3.59-$209.25M-$0.64-3.31 Is CLLS or ESPR more profitable? Esperion Therapeutics has a net margin of -29.37% compared to Cellectis' net margin of -234.39%. Esperion Therapeutics' return on equity of 0.00% beat Cellectis' return on equity.Company Net Margins Return on Equity Return on Assets Cellectis-234.39% -74.55% -22.65% Esperion Therapeutics -29.37%N/A -10.77% Does the media refer more to CLLS or ESPR? In the previous week, Esperion Therapeutics had 6 more articles in the media than Cellectis. MarketBeat recorded 10 mentions for Esperion Therapeutics and 4 mentions for Cellectis. Esperion Therapeutics' average media sentiment score of 0.85 beat Cellectis' score of 0.72 indicating that Esperion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, CLLS or ESPR? Cellectis has a beta of 3.1, indicating that its stock price is 210% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Does the MarketBeat Community prefer CLLS or ESPR? Esperion Therapeutics received 207 more outperform votes than Cellectis when rated by MarketBeat users. Likewise, 69.85% of users gave Esperion Therapeutics an outperform vote while only 65.75% of users gave Cellectis an outperform vote. CompanyUnderperformOutperformCellectisOutperform Votes40765.75% Underperform Votes21234.25% Esperion TherapeuticsOutperform Votes61469.85% Underperform Votes26530.15% Do analysts rate CLLS or ESPR? Cellectis currently has a consensus price target of $7.00, indicating a potential upside of 274.33%. Esperion Therapeutics has a consensus price target of $8.17, indicating a potential upside of 285.22%. Given Esperion Therapeutics' higher possible upside, analysts clearly believe Esperion Therapeutics is more favorable than Cellectis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do institutionals & insiders have more ownership in CLLS or ESPR? 63.9% of Cellectis shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 1.0% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryEsperion Therapeutics beats Cellectis on 10 of the 18 factors compared between the two stocks. Ad Investors AlleyStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!Click here to see this breakthrough before everyone else → Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLLS vs. The Competition Export to ExcelMetricCellectisBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$103.94M$2.94B$5.12B$8.72BDividend YieldN/A1.81%5.18%4.07%P/E Ratio-1.4420.4872.8114.16Price / Sales11.31224.491,250.2081.71Price / CashN/A176.6640.7036.03Price / Book0.804.056.455.94Net Income-$101.06M-$42.42M$119.73M$225.73M7 Day Performance5.65%-10.63%-5.13%-1.34%1 Month Performance-2.09%-5.81%-2.71%1.15%1 Year Performance-36.18%24.19%31.08%24.02% Cellectis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLLSCellectis3.6005 of 5 stars$1.87-2.1%$7.00+274.3%-28.6%$103.94M$9.19M-1.44290Analyst ForecastShort Interest ↓Gap UpESPREsperion Therapeutics4.1036 of 5 stars$2.23-8.2%N/A+91.0%$439.40M$116.33M-3.48240Analyst DowngradeRNACCartesian Therapeutics2.9192 of 5 stars$17.12+1.1%N/AN/A$435.11M$54.10M-0.3237Gap UpDSGNDesign Therapeutics1.1929 of 5 stars$7.50+8.5%N/A+163.6%$424.65MN/A-8.8240AKBAAkebia Therapeutics4.0582 of 5 stars$1.92-1.5%N/A+81.0%$418.91M$194.62M-8.35167VALNValneva2.5777 of 5 stars$5.07+5.8%N/A-63.5%$411.94M$165.52M-39.00700News CoverageGap DownFDMT4D Molecular Therapeutics2.9925 of 5 stars$7.71-2.0%N/A-19.9%$400.69M$20.72M-3.35201Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageAMLXAmylyx Pharmaceuticals3.2331 of 5 stars$5.68-9.0%N/A-60.8%$389.36M$380.79M-1.49200Short Interest ↑TNGXTango Therapeutics2.041 of 5 stars$3.56+6.3%N/A-48.7%$382.42M$36.53M-3.0290Analyst RevisionHigh Trading VolumeCYRXCryoport2.7246 of 5 stars$7.67-3.5%N/A-47.7%$379.13M$233.26M-2.271,170NLTXNeoleukin TherapeuticsN/A$40.00-44.1%N/A+162.3%$375.92MN/A-12.8690Gap DownHigh Trading Volume Related Companies and Tools Related Companies ESPR Alternatives RNAC Alternatives DSGN Alternatives AKBA Alternatives VALN Alternatives FDMT Alternatives AMLX Alternatives TNGX Alternatives CYRX Alternatives NLTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLLS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
